A review of oral vaccination with transgenic vegetables

Microbes and Infection

Volumn 1, Issue 10, 1999, Pages 777-783

  Tacket, Carol O ^a   Mason, Hugh S ^b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b United States Department of Agriculture Agricultural Research Service and Boyce Thompson Institute for Plant Research   (United States)

Author keywords

Edible vaccines; Oral immunization; Transgenic plants

Indexed keywords

VACCINE;

ACTIVE IMMUNIZATION; DRUG DELIVERY SYSTEM; GENE TRANSFER; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TRANSGENIC PLANT; VACCINATION;

EID: 0032727666     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80080-X     Document Type: Review

References (42)

1. Institute of Medicine, New Vaccine Development: Establishing Priorities. Volume II, Diseases in Developing Countries, National Academy Press, Washington DC, 1986, pp. 1-16.
2. Ogra P.L., Chiba Y., Beutner K.R., Morag A., Vaccination by non-parenteral routes: characteristics of immune response, Dev. Biol. Stand. 33 (1976) 19-26.
3. Mestecky J., McGhee J.R., Oral immunization: past and present, Curr. Top. Microbiol. Immunol. 146 (1989) 1-11.
4. Holmgren J., Clemens J., Sack D., Sanchez D., Svennerholm A.M., Development of oral vaccines with special reference to cholera, in: Bteimer D.D., Crommelin J.D., Midha K.K. (Eds.), Topics in pharmaceutical sciences, Amsterdam Medical Press, Amsterdam, 1989, pp. 297-302.
5. Ogra PL., Fishaut M., Gallagher M.R., Vaccination via the mucosal routes, Rev. Infect. Dis. 2 (1980) 352-369.
6. Kotloff K.L., Wasserman S.S., O'Donnell S., Losonsky G.A., Cryz S.J., Levine M.M., Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized placebo-controlled double-blind crossover trial, Infect. Immun. 6 (1992) 4430-4432.
7. Black R., Levine M.M., Young C., Rooney J., Levine S., Clements M.L., O'Donnell S., Hughes T., Germanier R., Chilean Typhoid Committee, Immunogenicity of Ty21a attenuated Salmonella typhi given with sodium bicarbonate or in enteric-coated capsules, Devel. Biol. Stand. 53 (1983) 9-14.
8. D' Amelio R., Tagliabue A., Nencioni L., Di Addario A., Villa L., Manganaro M., Boraschi D., LeMoli S., Nisini R., Matricardi P.M., Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines, Infect. Immun. 56 (1988) 2731-2735.
9. Rennels M.B., Rotavirus vaccine comes of age, J. Pediatr. 131 (1997) 632-638.
10. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., Bernstein D.I., Hayden EG., KotlofTK.K., Zangwill K., Iacusio D., Wolff M., The efficacy of live attenuated cold-adapted trivalent intranasal influenzavirus vaccine in children, N. Engl. J. Med. 338 (1998) 1405-1412.
11. Immunopotentiation, adjuvants, nonliving antigen delivery systems and naked DNA vaccines, in: Levine M.M., Woodrow G.G., Kaper J.B., Cobon G.S. (Eds.), New Generation Vaccines, 2nd Edition, Marcel Dekker Inc., New York, 1997, pp. 173-295.
12. Tacket C.O., Forrest B., Morona R., Attridge S.R., Labrooy J., Tall B.D., Reymann M., Rowley D., Levine M.M., Safety immunogenicity and efficacy against cholera challenge in man of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a, Infect. Immun. 58 (1990) 1620-1627.
13. Black R.E., Levine M.M., Clements M.L., Losonsky G., Herrington D., Berman S., Formal S.B., Prevention of shigellosis by a Salmonella typhi-Shigella sonnet bivalent vaccine, J. Infect. Dis. 155 (1987) 1260-1264.
14. Acheson D.W., Levine M.M., Kaper J.B., Keusch G.T., Protective immunity to Shiga-like toxin I following immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR, Infect. Immun. 64 (1996) 355-357.
15. Chen I., Finn T.M., Yanqing L., Guoming Q., Rappuoli R., Pizza M., A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussin tracheal colonization factor, Infect. Immun. 66(1998) 1648-1653.
16. Tacket CO., Losonsky G., Lubeck M.D., Davis A.R., Mizutani S., Horwith G., Hung P., Edelman R., Levine M.M., Initial safety and immunogenicity studies of an oral recombinant adenohepatitis vaccine, Vaccine 10 (1992) 673-676.
17. Cooneye L., Collier A.C., Greenberg P.D., Coombs R.W., ZarlingJ., Arditti D.E., Hoffman M.C., HuS.L., Corey L., Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein, Lancet 337 (1991) 567-572.
18. Hone D.M., Tacket C.O., Harris A., Bay B., Losonsky G., Levine M.M., Evaluation of a double aro mutant of Salmonella typhi ISP1820 in volunteers and in U937 human macrophage-like cells, J. Clin. Invest. 90 (1992) 412-420.
19. Pen J., Comparison of host systems for the production of recombinant proteins in: Owen M.R.L., Pen J. (Eds.), Transgenic plants: a production system for industrial and pharmaceutical proteins, John Wiley and Sons Ltd, 1996, pp. 149-167.
20. Ma J.K.C., Hiatt A., Hein ML, Vine N.D., Wang F., Stabila P., Van Dolleweerd C., Mostov K., Lehner T., Generation and assembly of secretory antibodies in plants, Science 268 (1995)716-719.
21. MaJ.K.C., Hikmat B.Y., Wycoff K., Vine N.D., Chargelegue D., Yu L., Hein M.B., Lehner T., Characterization of a recombinant plant monoclonal secretory antibody in preventive immunotherapy in humans, Nature Med. 4 (1998) 601-606.
22. Mason H.S., Arntzen C.J., Transgenic plants as vaccine production systems, Trends Biotechnol. 13 (1995) 388-392.
23. Zambryski P., Basic processes underlying Agrobacteriummediated DNA transfer to plant cells, Annu. Rev. Genet. 22 (1988) 1-30.
24. Herman L., Jacobs A., VanMontagu M., Depicker A., Plant marker gene fusion assay for study of normal and truncated T-DNA integration events, Mol. Gen. Genet. 224 (1990) 248-256.
25. Mason H.S., Haq TA., Clements J.D., Arntzen C.J., Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene, Vaccine 16 (1998) 1336-1343.
26. Mason H.S., Ball J.M., She J.J., Jiang X., Estes M.K., Arntzen C.J., Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice, Proc. Nad. Acad. Sei. USA 93 (1996) 5335-5340.
27. Arntzen C.J., Mason H.S., Oral vaccine production in the edible tissues of transgenic plants, in: Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. (Eds.), in New Generation Vaccines, Second Edition, Marcel Dekker, New York, 1997, pp. 263-277.
28. Mason H.S., Lam D.M.K., Arntzen C.J., Expression of hepatitis B surface antigen in transgenic plants, Proc. Natl. Acad. Sci. USA 89 (1992) 11745-11749.
29. Haq T.A., Mason H.S., Clements J.D., Arntzen C.J., Oral immunisation with a recombinant bacterial antigen produced in transgenic plants, Science 268 (1995) 714-716.
30. Strober W., Kelsall B., Marth T., Oral tolerance, J. Clin. Immunol. 18(1998) 1-30.
31. Weiner H.L., Oral tolerance, Proc. Natl. Acad. Sci. USA 91 (1994)10762-10765 .
32. Sixma T.K., Pronk E.S., Kalk K.H., Wartna E.S., vanZanten B.A., Witholt B., Hol W.G., Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli, Nature 351 (1991) 371-377.
33. Black R.E., Levine M.M., Clements M.L., Young C.R., Svennerholm A.M., Holmgren J., Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin, Infect. Immun. 55 (1987) 1116-1120.
34. Pizza M., Domenighini M., Hol W., Giannelli V., Fontana M.R., Giuliani M.M., Magagnoli C, Peppoloni S., Manetti R., Rappuoli R., Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis, Mol. Microbiol. 14 (1994) 51-60.
35. Yamamoto S., Takeda Y, Yamamoto M., Kurazone H., Imaoka K., Yamamoto M., Fujihashi K., Noda M., Kiyono H., McGhee J.R., Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity, J. Exp. Med. 185 (1997) 1203-1210.
36. Tacket C.O., Mason H.S., Losonsky G., Clements J.D., Levine M.M., Atntzen C.J., Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato, Nature Med. 4 (1998) 607-609.
37. ArakawaT., Chong D.K.X., Langridge W.H.R., Efficacy of a food plant-based oral cholera toxin B subunit vaccine, Nature Biotech. 16 (1998) 292-297.
38. Thanavala Y., Yang Y.F., Lyons P., Mason H.S., Arntzen C., Immunogenicity of transgenic plant-derived hepatitis B surface antigen, Proc. Natl. Acad. Sci. USA 92 (1995) 3358-3361.
39. Ma S.W., Zhao D.L., Yin Z.Q., Mukherjee R., Singh B., Qin H.Y., Stiller C.R., Jevnikar A.M., Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance, Nature Med. 3 (1997) 793-796.
40. Arakawa T, Yu J., Chong D.K.X., Hough J., Engen P.C., Langridge W.H.R., A plant-based choleta toxin B subunitinsulin fusion protein protects against the development of autoimmune diabetes, Nature Biotech. 16 (1998) 934-938.
41. Tacket C.O., Reid R.H., Boedeker E.G., Losonsky G., NataroJ.P., Bhagat H., Edelman R., Enterai immunization and challenge of volunteers given enterotoxigenic E, coli CFA/II encapsulated in biodegradable microspheres, Vaccine 12 (1994) 1270-1274.
42. Dickinson B.L., Clements J.D., Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADPribosyltransferase activity, Infect. Immun. 63 (1995) 1617-1623.